Literature DB >> 15167512

Natural history, diagnosis, treatment and outcome of papillary thyroid microcarcinoma (PTMC): a mono-institutional 12-year experience.

Maria Rosa Pelizzo1, Isabella Merante Boschin, Antonio Toniato, Costantino Pagetta, Andrea Piotto, Paolo Bernante, Dario Casara, Gianmaria Pennelli, Domenico Rubello.   

Abstract

The clinical and histopathological records of 149 consecutive patients with papillary thyroid microcarcinoma (PTMC), homogeneously studied and operated on by the same surgeon in the period 1990 to 2001, were reviewed. After a mean 6.5-year follow-up, three cases of loco-regional recurrence (2%) were observed. These three patients had all undergone partial thyroidectomy only and tumour relapse occurred in the residual thyroid tissue. No recurrence was observed in patients treated by total thyroidectomy and I. At variance with other reported series, no lymph node recurrence was observed in our series, in particular in the group of 23 patients with evidence of nodal metastases at initial diagnosis (three of whom were revealed by I scan after surgery). Therefore, a preventive effect of I treatment in our patient population can be hypothesized. However, prolonged follow-up will be necessary to clarify this. Due to the inability of current imaging modalities to select pre-operatively PTMC patients at risk for recurrence (presence of thyroid capsular invasion, multifocality and microscopic lymph node metastases), it appears reasonable to offer the patient total thyroidectomy when a pre-operative diagnosis of PTMC is reached. Moreover, the policy of our thyroid cancer centre is that, in these patients, post-surgical I scan should be obtained in order to detect unknown metastatic deposits, and I treatment should also be considered in patients with poor clinical and histopathological prognostic factors. In contrast, in patients operated on for benign thyroid disease and with delayed diagnosis of PTMC at definitive histopathological examination, re-operation might be avoided in the presence of unifocal disease without thyroid capsular invasion and with ultrasound-'normal' residual thyroid tissue. Close clinical and ultrasound follow-up is recommended, especially in patients who have undergone conservative surgery only.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15167512     DOI: 10.1097/01.mnm.0000126625.17166.36

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN: 0143-3636            Impact factor:   1.690


  37 in total

1.  Total versus hemithyroidectomy for microscopic papillary thyroid cancer.

Authors:  M Gershinsky; O Barnett-Griness; N Stein; D Hirsch; G Tzvetov; O Bardicef; J Pauker; S Grozinsky-Glasberg; S Ish-Shalom; I Slutski; I Shimon; C Benbassat
Journal:  J Endocrinol Invest       Date:  2011-09-27       Impact factor: 4.256

2.  'Aggressive papillary' thyroid microcarcinoma.

Authors:  Cyril Page; Aurélie Biet; Pierrick Boute; Philippe Cuvelier; Vladimir Strunski
Journal:  Eur Arch Otorhinolaryngol       Date:  2009-03-18       Impact factor: 2.503

3.  One should not just read what one believes: the nearly irresolvable issue of producing truly objective, evidence-based guidelines for the management of differentiated thyroid cancer.

Authors:  Markus Dietlein; F A Verburg; M Luster; C Reiners; F Pitoia; H Schicha
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-05       Impact factor: 9.236

4.  Retrospective Analysis of 255 Papillary Thyroid Carcinomas ≤2 cm: Clinicohistological Features and Prognostic Factors.

Authors:  Pedro Marques; Valeriano Leite; Maria João Bugalho
Journal:  Eur Thyroid J       Date:  2014-12-06

5.  Incidental thyroid carcinomas. A retrospective study.

Authors:  A Maturo; L Tromba; L De Anna; G Carbotta; G Livadoti; C Donello; F Falbo; G Galiffa; Antonella Esposito; A Biancucci; S Carbotta
Journal:  G Chir       Date:  2017 Mar-Apr

6.  BRAF V600E mutation is associated with tumor aggressiveness in papillary thyroid cancer.

Authors:  Su-jin Kim; Kyu Eun Lee; Jun Pyo Myong; Jeong-hwan Park; Yoon Kyung Jeon; Hye Sook Min; So Yeon Park; Kyeong Cheon Jung; Do Hoon Koo; Yeo-Kyu Youn
Journal:  World J Surg       Date:  2012-02       Impact factor: 3.352

7.  Guidelines for radioiodine therapy of differentiated thyroid cancer.

Authors:  M Luster; S E Clarke; M Dietlein; M Lassmann; P Lind; W J G Oyen; J Tennvall; E Bombardieri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-10       Impact factor: 9.236

8.  Preoperative prediction of central lymph node metastasis in thyroid papillary microcarcinoma using clinicopathologic and sonographic features.

Authors:  Kyung-Eun Kim; Eun-Kyung Kim; Jung Hyun Yoon; Kyung Hwa Han; Hee Jung Moon; Jin Young Kwak
Journal:  World J Surg       Date:  2013-02       Impact factor: 3.352

9.  Nodal metastasis and recurrence in papillary thyroid microcarcinoma.

Authors:  Adolfo Pisanu; Alessandra Saba; Mauro Podda; Isabella Reccia; Alessandro Uccheddu
Journal:  Endocrine       Date:  2014-07-10       Impact factor: 3.633

10.  Risk factors for nodal metastasis and recurrence among patients with papillary thyroid microcarcinoma: differences in clinical relevance between nonincidental and incidental tumors.

Authors:  Adolfo Pisanu; Isabella Reccia; Oreste Nardello; Alessandro Uccheddu
Journal:  World J Surg       Date:  2009-03       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.